S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Amicus Therapeutics Stock Forecast, Price & News

+0.13 (+1.26 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $10.48
50-Day Range
MA: $16.82
52-Week Range
Now: $10.48
Volume4.61 million shs
Average Volume4.57 million shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.
Amicus Therapeutics logo


Newell Brands, Amicus fall; HubSpot, Cognex rise
February 12, 2021 |  marketbeat.com
Amicus Therapeutics: Q4 Earnings Insights
March 2, 2021 |  finance.yahoo.com
Amicus Therapeutics FY 2020 top line up 43%
March 1, 2021 |  seekingalpha.com
Earnings Preview for Amicus Therapeutics
February 26, 2021 |  finance.yahoo.com
Amicus Therapeutics Becomes Oversold (FOLD)
February 12, 2021 |  nasdaq.com
Amicus shares rise on acquisition speculation from Vertex
February 4, 2021 |  seekingalpha.com
FOLD Feb 2021 31.000 call
January 28, 2021 |  au.finance.yahoo.com
FOLD Feb 2021 20.000 put
January 28, 2021 |  au.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FOLD
Year FoundedN/A



Sales & Book Value

Annual Sales$182.24 million
Book Value$1.87 per share


Net Income$-356,390,000.00
Net Margins-120.18%


Market Cap$2.77 billion
Next Earnings Date5/6/2021 (Estimated)


Overall MarketRank

1.56 out of 5 stars

Medical Sector

401st out of 1,968 stocks

Pharmaceutical Preparations Industry

198th out of 771 stocks

Analyst Opinion: 4.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+0.13 (+1.26 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amicus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FOLD, but not buy additional shares or sell existing shares.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Amicus Therapeutics?

Wall Street analysts have given Amicus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Amicus Therapeutics

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its earnings results on Sunday, February, 28th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.04. Amicus Therapeutics had a negative trailing twelve-month return on equity of 73.81% and a negative net margin of 120.18%.
View Amicus Therapeutics' earnings history

How has Amicus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 30.2% and is now trading at $10.48.
View which stocks have been most impacted by COVID-19

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $261-261 million, compared to the consensus revenue estimate of $259.24 million.

What price target have analysts set for FOLD?

13 brokers have issued 12 month price objectives for Amicus Therapeutics' shares. Their forecasts range from $12.50 to $31.00. On average, they expect Amicus Therapeutics' stock price to reach $20.19 in the next year. This suggests a possible upside of 92.7% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 54, Pay $1.96M)
  • Mr. Bradley L. Campbell M.B.A., Pres, COO & Director (Age 45, Pay $899.2k)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 55, Pay $630.45k)
  • Dr. Hung Viet Do, Chief Scientific Officer (Age 53, Pay $637.43k)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 58, Pay $686.59k)
  • Ms. Samantha Prout, VP of Fin., Global Controller & Principal Accounting Officer (Age 43)
  • Dr. Enrique Diloné, Sr. VP of Technical Operations (Age 54)
  • Andrew Faughnan, Director of Investor Relations
  • Mr. Patrik S. Florencio, Sr. VP, Global Chief Compliance & Risk Officer
  • Ms. Diana Moore, Head of Global Corp. Communications

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.40%), Morgan Stanley (4.89%), Janus Henderson Group PLC (4.32%), Avoro Capital Advisors LLC (3.45%), Lone Pine Capital LLC (2.56%) and Northern Trust Corp (1.24%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Avoro Capital Advisors LLC, Clearbridge Investments LLC, UBS Asset Management Americas Inc., Victory Capital Management Inc., Dimensional Fund Advisors LP, Panagora Asset Management Inc., and Peregrine Capital Management LLC. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was purchased by a variety of institutional investors in the last quarter, including Lone Pine Capital LLC, Norges Bank, Morgan Stanley, Canada Pension Plan Investment Board, BlackRock Inc., Price T Rowe Associates Inc. MD, Rice Hall James & Associates LLC, and Cardan Capital Partners LLC.
View insider buying and selling activity for Amicus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $10.48.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $2.77 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 584 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]

This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.